K-1000 Chewable Tablets (1 Box = 30 Tablets)

Certain immune system disorder (Sarcoidosis). Cholecalciferol is advised to be prescribed with caution to patients suffering from sarcoidosis because of the risk of increased metabolism of Vitamin D3 to its active form. These patients is advised to be monitored with regard to the calcium content in serum and urine.
Liver disease. In patients with liver impairment, Vitamin D3 absorption may be markedly impaired; conversion to active metabolite calcifediol may be reduced significantly, with the requirement of high doses of cholecalciferol. Agents not requiring hepatic hydroxylation are preferred in this condition. It is not reasonable to use cholecalciferol in severe liver impairment .
Untreated phosphate imbalance. There is a risk of metastatic calcification; normalization of phosphate levels is indicated prior to therapy with cholecaciferol. Avoid exceed the recommended dose.